HC Wainwright Reaffirms “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT)

HC Wainwright reissued their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT – Free Report) in a research report released on Tuesday morning, Benzinga reports. They currently have a $51.00 price objective on the biotechnology company’s stock. A number of other brokerages have also recently commented on ARCT. StockNews.com began coverage on Arcturus Therapeutics in […]

Leave a Reply

Your email address will not be published.

Previous post Baidu (NASDAQ:BIDU) PT Lowered to $150.00 at Susquehanna
Next post Does the Unique GMA T.50 Live Up to Expectations?